Reliable and fast diagnostics of cervical cancer While HPV tests detect infections with HPV and thus allow drawing conclusions on the risk of developing cervical cancer, the GynTect® test can be used in a second step to clarify whether affected cells are actually already developing into cancer cells based on the detection of epigenetic markers. […]
Since end of 2020, different SARS-CoV-2 variants have appeared worldwide − alpha (B.1.1.7), beta (B.1.351), gamma (P.1/B.1.1.128) and delta (B1.617.2) − which are in part more contagious than the original virus type and are therefore spreading more quickly within populations. These variants reveal genetic changes (mutations) in the so-called receptor binding domain (RBD), which is
Six months after the start of the COVID-19 vaccination campaign in Germany, half of the population has received at least one vaccination dose. According to the Federal Ministry of Health, 37.9% of them have already been fully vaccinated (as of 02.07.2021). Currently there are four different COVID-19 vaccines available in Germany, which differ slightly in
Press Release Jena / Lübeck (GER) – Biotechnology company oncgnostics GmbH is announcing a collaboration with the international diagnostics group EUROIMMUN Medizinische Labordiagnostika AG. As part of the cooperation, EUROIMMUN will sell the cervical cancer test from oncgnostics GmbH, Gyn-Tect, in the European countries of Portugal, Italy, Turkey and Poland. The test is also expected
Notification EUROIMMUN AG from Lübeck in Germany, a manufacturer of reagents and automated systems for medical laboratory diagnostics, has developed a PCR test for direct virus detection, in addition to the assays for the detection of antibodies against SARS-CoV-2 (ELISA). The new test is a real-time reverse transcriptase PCR used to detect the genetic material
